Key Highlights
- Dr. Gregg A. Pratt joins as Chief Regulatory and Quality Assurance Officer to oversee regulatory and quality functions.
- Phase 3 trials for MM120 ODT in generalized anxiety disorder (GAD) and major depressive disorder (MDD) are imminent.
- Dr. Pratt’s appointment underscores MindMed’s commitment to regulatory excellence and transformative brain health therapies.
Source: Business Wire
Notable Quotes
- “Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs…will be key as we advance our Phase 3 programs.” — Rob Barrow, CEO at MindMed
- “The therapeutic potential of MM120 ODT…inspired me to join MindMed in pursuing what could be one of the most meaningful breakthroughs in the field of psychiatry.” — Dr. Gregg A. Pratt, Chief Regulatory and Quality Assurance Officer at Mind Medicine (MindMed) Inc
SoHC's Take
Dr. Pratt’s appointment is a significant strategic move as MindMed approaches pivotal Phase 3 trials for MM120 ODT, targeting two of the most challenging brain health disorders. His proven track record in securing FDA approvals for innovative psychiatric treatments highlights MindMed’s serious commitment to advancing regulatory pathways and delivering transformative solutions. With a robust leadership team and a promising product pipeline, MindMed is well-positioned to make a profound impact on brain health treatment landscapes.
